Kim Jihee, Kim Bomi, Kim Soomin, Lee Young In, Kim Jemin, Lee Ju Hee
Department of Dermatology and Cutaneous Biology Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Scar Laser and Plastic Surgery Center, Yonsei Cancer Hospital, Seoul, Korea.
J Cosmet Dermatol. 2020 Mar;19(3):651-656. doi: 10.1111/jocd.13063. Epub 2019 Jul 22.
Ablative CO2 fractional laser (AFL) is a common cosmetic procedure to improve skin laxity. However, due to prolonged downtime and the risk of postinflammatory hyperpigmentation, laser-assisted delivery of active ingredients as post-laser treatment has gained interest in past years. Among various active ingredients, human umbilical cord blood-derived mesenchymal stem cells (hUCBMSCs) can be a promising agent promoting skin regeneration.
We evaluated the efficacy and safety of a human cord blood cell-conditioned media containing serum and cream on patients who underwent AFL treatment. A randomized, investigator-blinded, prospective, split-face comparison study was conducted.
Twenty-three patients who underwent AFL on both cheeks applied a human umbilical cord blood-derived mesenchymal stem cell (hUCBMSC)-conditioned media containing cream with or without stem cell containing serum application. As a primary outcome measure, we evaluated the total area of microcrusts and post-treatment erythema using digital photographs. Additionally, skin biophysical parameters (corneometer, TEWL) and global improvement scores for skin texture were assessed.
The area of total microcrusts was reduced in the study group which applied both serum and cream. The global improvement score of the post-treatment erythema was significantly reduced. Investigator-assessed global improvement scores were higher in the combination treatment group. Additionally, there was no adverse event, which was associated with the use of either hUCBMSCs containing serum or cream.
The application of human cord blood cell containing serum and cream resulted in accelerated wound healing and reduced post-treatment erythema, which effectively reduced recovery time after ablative laser treatment.
剥脱性二氧化碳点阵激光(AFL)是一种改善皮肤松弛的常见美容手术。然而,由于恢复期长以及有炎症后色素沉着的风险,近年来激光辅助递送活性成分作为激光后治疗受到关注。在各种活性成分中,人脐带血来源的间充质干细胞(hUCBMSCs)可能是促进皮肤再生的有前景的药物。
我们评估了含血清和乳膏的人脐带血细胞条件培养基对接受AFL治疗患者的疗效和安全性。进行了一项随机、研究者盲法、前瞻性、半脸对照研究。
23名双侧脸颊接受AFL治疗的患者,应用含人脐带血来源间充质干细胞(hUCBMSC)的条件培养基乳膏,同时或不应用含干细胞的血清。作为主要结局指标,我们使用数码照片评估微痂总面积和治疗后红斑情况。此外,评估皮肤生物物理参数(角质层水合度测定仪、经表皮水分流失)以及皮肤质地的整体改善评分。
同时应用血清和乳膏的研究组微痂总面积减少。治疗后红斑的整体改善评分显著降低。研究者评估的联合治疗组整体改善评分更高。此外,未出现与使用含hUCBMSCs的血清或乳膏相关的不良事件。
应用含人脐带血细胞的血清和乳膏可加速伤口愈合并减轻治疗后红斑,有效缩短剥脱性激光治疗后的恢复时间。